1192322-52-3

Upstream product

• 56531-55-6 3-(4-hydroxyphenyl)adamantane-1-carboxylic acid 
• 1192322-46-5 3-(4-Hydroxyphenyl)-adamantane-1-carboxylic acid benzyl ester 
• 56531-56-7 3-(4-methoxyphenyl)adamantane-1-carboxylic acid 
• 828-51-3 1-Adamantanecarboxylic acid 
• 21816-08-0 3-bromoadamantane-1-carboxylic acid 
• 1192322-49-8 3-(4-ethoxycarbonylmethoxyphenyl)adamantane-1-carboxylic acid benzylester 

Downstream Products

• 1192322-53-4 3-(4-[(3-methoxycarbonylphenylcarbamoyl)methoxy]phenyl)adamantane-1-carboxylic acid benzylester 
• 1192322-55-6 3-{4-[(3-methoxycarbonyl-phenyl-carbamoyl)-methoxy]-phenyl}-adamantane-1-carboxylic acid 
• 1192322-78-3 3-{4-[(3-methoxycarbonylphenylcarbamoyl)-methoxy]-phenyl}-[4-(4-fluorobenzyl) piperazin-1-yl]-adamantan-1-ylmethanone 
• 1192322-80-7 3-{4-[(3-methoxycarbonylphenylcarbamoyl)-methoxy]-phenyl}-[4-(4-methoxybenzyl)piperazin-1-yl]-adamantan-1-ylmethanone 

Relevant academic research and scientific papers

Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, and pharmaceutical composition and kit for inhibiting the growth of cancer containing the same as an active ingredient

The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adamantyl derivative according to the present invention suppresses the growth of cancer cells by targeting mitochondria ETC complex I and damaging the metabolism of cancer cells, and thus can be useful as an anticancer pharmaceutical composition that is a powerful therapeutic agent for cancer dependent on oxidative phosphorylation for producing ATP.

NOVEL DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PRODUCTION METHOD FOR SAME, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER METASTASIS COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1α, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, β-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.

A novel class of highly potent multidrug resistance reversal agents: Disubstituted adamantyl derivatives

Novel disubstituted adamantyl derivatives were synthesized and evaluated in a P-glycoprotein dependent multidrug resistance cancer cell line. The hit to lead optimization provided potent MDR reversal agents. Some potent adamantyl derivatives were more than 10-fold more potent than verapamil without considerable intrinsic cytotoxicity. The 3-trifluorophenyl derivative 14f did not affect the metabolism of CYP450 3A4, whereas most of MDR revertants had a weak inhibitory effect.